LI
AKBA icon

Leap Investments’s Akebia Therapeutics AKBA Stock Holding History

Leap Investments’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$148K Sell
10,900
-43,800
-80% -$453K 0.1% 326
2020
Q1 		$415K Buy
+54,700
New +$426K 0.61% 18

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Leap Investments's AKBA Position: Q2 2020 in Review

Leap Investments reduced its Akebia Therapeutics (AKBA) stake by 80% in Q2 2020, selling an estimated $453K and leaving 10,900 shares worth $148K. The position accounts for 0.1% of the portfolio, ranked #326.

Leap Investments first reported a position in AKBA in Q1 2020 and has held it in 2 quarters since. The position peaked at $415K in Q1 2020. 189 funds tracked by Wall St. Rank hold AKBA as of Q2 2020.

  • Leap Investments held 10,900 shares of Akebia Therapeutics worth $148K as of Q2 2020.
  • Leap Investments sold 43,800 Akebia Therapeutics shares in Q2 2020, an estimated $453K.
  • Akebia Therapeutics made up 0.1% of Leap Investments's portfolio in Q2 2020, its #326 holding.
  • Leap Investments first reported a position in Akebia Therapeutics in Q1 2020 and has held it in 2 quarters since.
  • Leap Investments's Akebia Therapeutics position peaked at $415K in Q1 2020.
  • 189 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2020.

Based on Leap Investments's 13F filing for Q2 2020, filed 3 Aug 2020.